Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 17, 2009

EMBL Licenses Tripos' Software to Advance Drug Discovery

EMBL Licenses Tripos' Software to Advance Drug Discovery

EMBL to advance drug discovery research with Tropos' software

  • The European Molecular Biology Laboratory (EMBL) signed an agreement to license Tripos' Themis and Surflex-Dock software to advance its drug discovery efforts within chemical biology.

    The software will be used to enable small molecule development among research groups in the Chemical Biology Core Facility, a three-way collaboration between the EMBL, the German Cancer Research Center, and the University of Heidelberg.

    The EMBL says that in studies to assess Surflex-Dock, the software yielded promising compound candidates for testing in about two days.

    It docked five million structures of the research institute's virtual database of commercially available compounds into a binding site of a project's receptor structure.

    Additionally, in the first experiments with Themis, the software provided new chemical ideas that would contribute to drug discovery projects, adds Joe Lewis, Ph.D, head of the facility.ADNFCR-2184-ID-19031149-ADNFCR



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »